Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®

PHASE1CompletedINTERVENTIONAL

Enrollment

225

Participants

Timeline

Start Date

June 5, 2024

Primary Completion Date

July 22, 2025

Study Completion Date

July 22, 2025

Conditions

Healthy Participants

Interventions

DRUG

MAB-22

60mg dose of a single subcutaneous injection

DRUG

EU-Prolia®

60mg dose of a single subcutaneous injection

DRUG

US-Prolia®

60mg dose of a single subcutaneous injection

Trial Locations (2)

Xentria Investigative Site, Budapest

Xentria Investigative Site, Groningen

All Listed Sponsors

lead

Xentria, Inc.

INDUSTRY

NCT06310824 - Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia® | Biotech Hunter | Biotech Hunter